A drug candidate developed at King's College London, designated KCL-286, has demonstrated the ability to repair dangerous neuronal DNA damage and significantly reduce neuroinflammation in mouse models of Alzheimer's disease. Unlike the dominant therapeutic paradigm that has focused almost exclusively on amyloid plaque clearance, KCL-286 targets multiple disease-related pathways simultaneously addressing both the DNA damage response and inflammatory cascades that occur very early in Alzheimer's progression.
The compound has been confirmed as safe for human use, positioning it for potential clinical trials. Researchers at KCL and reported by Drug Target Review described the approach as a "broader therapeutic strategy" than single-target amyloid treatments, which have repeatedly failed to deliver meaningful cognitive improvement in late-stage trials.
The findings were published by King's College London. [1]